Methods
Oral cabozantinib
(25mg/m2)
was administered daily for 21 (dose level 1) or 14 (dose level -1B)
days. Topotecan (0.75mg/m2) and cyclophosphamide
(250mg/m2) were administered IV on days 1-5. A
modified 3+3 design based upon first cycle dose-limiting toxicities
(DLT) was used for dose escalation.